Oxymorphone Hydrochloride

Danger

H301 (18.8%): Toxic if swallowed [Danger Acute toxicity, oral]；H302 (81.2%): Harmful if swallowed [Warning Acute toxicity, oral]；H310 (81.2%): Fatal in contact with skin [Danger Acute toxicity, dermal]；H311 (18.8%): Toxic in contact with skin [Danger Acute toxicity, dermal]；H315 (18.8%): Causes skin irritation [Warning Skin corrosion/irritation]；H317 (18.8%): May cause an allergic skin reaction [Warning Sensitization, Skin]；H319 (18.8%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]；H330 (81.2%): Fatal if inhaled [Danger Acute toxicity, inhalation]；H334 (18.8%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]；H361 (18.8%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

P203, P233, P260, P261, P262, P264, P264+P265, P270, P271, P272, P280, P284, P301+P316, P301+P317, P302+P352, P304+P340, P305+P351+P338, P316, P318, P320, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P361+P364, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 48 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Oxymorphone undergoes extensive hepatic metabolism in humans. After a 10 mg oral dose, 49% was excreted over a five-day period in the urine. Of this, 82% was excreted in the first 24 hours after administration. The recovered drug-related products contained the oxymorphone (1.9%), the conjugate of oxymorphone (44.1%), the 6(beta)-carbinol produced by 6-keto reduction of oxymorphone (0.3%), and the conjugates of 6(beta)-carbinol (2.6%) and 6(alpha)-carbinol (0.1%). Route of Elimination: Oxymorphone is highly metabolized, principally in the liver, and undergoes reduction or conjugation with glucuronic acid to form both active and inactive products. Because oxymorphone is extensively metabolized, <1% of the administered dose is excreted unchanged in the urine. Half Life: 1.3 (+/-0.7) hours

OXYMORPHONE HYDROCHLORIDE

Full Opioid Agonists [MoA]; Opioid Agonist [EPC]

Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS.

Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage.

Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS.